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Abstract Several clinical trials suggest that botulinum
toxin type-A (BTX-A) may be an effective treatment
option for patients with chronic tension-type headache
(CTTH); however, controversy remains as to how the
botulinum toxin optimally should be used for treating
headache and which patient’s profile fits this treatment. The
objective of this study was to evaluate the efficacy and
tolerability of BTX-A for the prophylactic treatment of
CCTH in Egyptian patients. This was a randomized, single-
blind, placebo-controlled study of BTX-A for the treatment
of patients aged 25–50 years old with CCTH. Following a
30-day screening, headache parameters and severity
assessed by the standard visual analogue scale (VAS), and
the 25-item Henry Ford Hospital Headache Disability
Inventory (HDI) were recorded as a baseline. Then,
injection was done with either BTX-A or with saline by a
combination of two methods for detecting injection sites
(the fixed-site approach and follow-the-pain approach).
Our study showed significant improvement after 1 month
of BTX-A injection regarding headache days/month,
severity measured by VAS and HDI in headache severity.
There was significant reduction of prophylactic medica-
tions, and there were minor complications, but these
reversed spontaneously without further treatment. BTX-A
was an effective and well-tolerated prophylactic treatment
in Egyptian patients with CCTH.
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Introduction
Tension-type headache (TTH) is a distressing condition
which, when chronic, can affect patients almost daily and
can often be difficult to treat effectively [1]. It is the most
common type of recurrent primary headache disorders that
induces significant functional limitations, and imposes
large individual and socio-economic burdens. Its life time
prevalence in general population ranges from 30 to 78%
[2]. TTH is included in the International Headache Society
(IHS) classification in 2004 [3], and is further categorized
as either episodic or chronic; it is also defined by whether
or not associated with pericranial tenderness.
The pathophysiology of TTH remains controversial [4–
6], pain etiology was presumed to be the muscular con-
traction of pain-sensitive structures of the cranium, but no
research supports muscular contraction as the sole pain
etiology [1]. Hence, the IHS intentionally abandoned the
terms ‘‘muscular contraction headache’’ and ‘‘tension
headache’’. Several other mechanisms have been proposed,
including central medullary mechanisms, that involve
altered stimulus response function of second-order trans-
mission neurons in the spinal cord or in the brain stem; and
central cortical mechanisms that involved disturbance of
limbic pathways to the brain stem and caused by dysreg-
ulated endogenous pain-control system [4, 7].
The therapeutic effect of botulinum toxin (BTX-A) in
headaches was serendipitously noted in 1992 by William
Binder who identified that patients with migraine head-
aches recovered from their attacks following BTX-A
injections for the treatment of facial wrinkles [8]. There-
after, BTX-A was increasingly considered a promising
preventive treatment for patients with refractory primary
headache disorders especially migraine and chronic tension
type headaches (CTTH) [7, 9–11]. However, by evaluating
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the use of BTX-A in different types of headaches in an
evidence-based manner, though most of the initial reports
on botulinum toxin in TTH and in migraine were positive
yet, these results were contradictory in well-designed,
randomized controlled trials [12, 13].
The proposed mechanism of effect of BTX-A in CTTH
was reduction of pericranial muscle tension by cholinergic
chemodenervation [14]; however, beyond this peripheral
mechanism that does not fit the pathophysiological concept
of all forms of headache [11, 15] BTX-A has an impact on
the neuronal signaling pathways activated during headache,
and it also exerts a blocking action on the parasympathetic
nervous system, and might inhibit release of other neuro-
transmitters or affect transmission of afferent neuronal
impulses [1]. Durham et al. [16] recognized that BTX-A
could inhibit calcium-dependant release of CGRP (calcito-
nin gene-related peptide) from stimulated trigeminal
neurons in an experimental model. Other studies have shown
that BTX-A interferes with other neurotransmitters and pain
modulators such as substance P that mediated by cleavage of
the intracellular effector SNAP-25 (synaptosome-associated
protein), bradykinin, and glutamate [17, 18].
The aim of this study was to evaluate the efficacy and
tolerability of BTX-A for prophylactic treatment of CTTH
in Egyptian patients.
Materials and methods
Study protocol and treatment
This was a randomized, single-blind, placebo-controlled
study that was conducted on 28 Egyptian patients to
determine the therapeutic effects of BTX-A (BOTOX,
Allergen) in CTTH. The study protocol was designed
according to the recommendations of the International
Headache Society (IHS), and it was conducted with the
approval of the Ethical Committee of National Cancer
Institute Cairo University. A written, informed consent was
obtained from all patients prior to the study commence-
ment following an explanation of the nature, duration, and
purpose of the study.
Screening phase
Prior to the study, the included patients were subjected to
thorough physical and neurological examination, all of
them had their routine hematological and biochemical
profile that included (complete blood count, blood sugar,
liver and kidney function tests), and CT scan brain. Patients
were requested to keep a headache diary for 1 month prior
to treatment and for 3 months posttreatment. Subjects
recorded in his/her diary the following headache
parameters in their provided diaries: headache duration,
number of headache days per month, the start and stop
times of headache, headache associated symptoms, number
of days with acute headache medications were taken, and
headache severity assessed by the standard visual analogue
scale (VAS) from 0 (no pain) to 10 (unbearable pain) [19].
After completing the 1-month period, they were subjected
to the baseline 25-item Henry Ford Hospital Headache
Disability Inventory (HDI, maximum score 100) [20]. All
these efficacy variables were assessed at baseline, 30 and
90 days after injection.
Participant characteristics
All participants included in this study had CTTH. The
diagnosis of CTTH was established according to the criteria
of the IHS (bilateral location, non-pulsating quality, with no
more than one of photophobia, phonophobia or mild nau-
sea). Eligibility criteria: patients were eligible in this study
when they had (1) headache on equal or more than 15 days
per month on average for at least 3 months; (2) headache
duration of 1–10 years; (3) history of failed treatment in the
last 3 months with at least one prophylactic drug (4) ability
to distinguish between the different headache types.
Exclusion criteria
(1) Patients with migraine or other forms of primary or
secondary headaches;
(2) Planned or actual pregnancy, lactation, or women of
childbearing age using inadequate contraceptive
measures;
(3) Any type of substance use disorders, those with
drug-induced headache, and patients with medications
overuse (simple analgesics, narcotic analgesics, and
benzodiazepines) in the last 2 years;
(4) Previous exposure to BTX-A, any neuromuscular
disease, or treatment with drugs affecting the neuromus-
cular junction;
(5) Prior injection of anesthetic or steroid into the
muscles to be injected in the month prior to study entry;
(6) Serious physical and psychiatric disease.
When the baseline diary confirmed the inclusion criteria, the
patients were randomized to receive injections of either BTX-
A (100 U BOTOX in 4 mL saline) or placebo (2 mL 0.9%
NaCl vial). Patients were allocated to one of the two treatment
groups by a computer-generated randomization list.
Injection technique
Patients were injected with BTX-A for only one session
and followed up for 3 months. We adopted a combination
28 J Headache Pain (2009) 10:27–34
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of two methods for detecting injection sites; fixed-site
approach and follow-the-pain approach [21, 22]. This
treatment paradigm was used to detect the most tender
points in a template of mostly affected muscles in patients
with CTTH. After placing the patient in a sitting position,
patients were questioned on the anatomic location of the
headache. Injected tender points were identified from the
potential tender points in the following muscles: frontalis,
temporalis, sternocleidomastoideus, trapezius, splenius
capitis, and semispinalis [22, 23]. Tender points were
identified by history-taking, and by manual palpation.
Intramuscular injections using sterile technique were
administered using 1-mL insulin syringes. BTX-A 100-U
vial was reconstituted with preservative-free 0.9% saline to
yield 2.5 U/0.1 mL. Tender points were then injected with
either BTX-A or saline. The chosen dose of BTX-A varied
among patients, but was the same for all injected tender
points in any one patient; the dose of BTX-A for different
muscles was adopted from Evers et al. [23] (Table 1), and
the dose ranged from 2 to 12 U per site. Dosage schedules
were decided according to the affected muscle size taking
into consideration that the doses injected in the cervical
shoulder girdle muscles are kept low, so as to prevent any
possible weakness [22]. Patients in the control group
received equivalent volumes of saline.
Outcome measures
The primary efficacy variables were headache days per
month and headache severity as measured by VAS, and
quality of life assessed by HDI. Secondary efficacy vari-
ables included, duration of headache per day (hours), and
number of days of symptomatic therapy per month. For all
patients, reassessment was done 30 and 90 days after
injection.
Safety measures
Any adverse event that a subject reported during the study
was recorded by the investigators, graded for severity
(mild, moderate, or severe), and assessed for its relation-
ship to study treatment (none, possible, probable, or
definite). A serious adverse event was defined as one that
was fatal, life-threatening, permanently disabling, or
required admission to hospital.
Data analysis
Management of data was carried out with the Statistical
Package for Social Sciences (version 12, SPSS Inc. Chi-
cago, IL, USA). Nominal data were analyzed using either
simple v2 test or Fisher exact probability test, depending on
sample size and expected frequencies. Ordinal measure-
ments were analyzed using independent t test. General
linear model by repeated measure ANOVA was generated
to assess changes of efficacy variables from baseline at 30




In total, 28 Egyptian patients with CTTH [9 (32.1%) males
and 19 (67.9%) females] were enrolled in this study during
the period from August 2006 to April 2007; and their
follow-up was completed by July 2007. Participants age
ranged from 25 to 50 years with a mean age of
(36.57 ± 7.61) years. Out of included patients 10 (35.7%)
were smokers, and 3/19 (15.79%) received contraceptive
pills. Eight (28.57%) of our patients received secondary
education, 15 (53.57%) has university graduation, and 5
(17.86%) had a higher educational level. Patients were
randomized to receive either BTX-A (n = 14) or placebo
‘‘saline’’ (n = 14). The demographic variables showed no
differences between both groups (Table 2).
Headache history
The headache duration ranged from 1 to 10 years with a
mean of (4.79 ± 2.57) years. All patients received pro-
phylactic treatment during the last 3 months before
enrollment (this includes multiple preventive strategies as
antiepileptic drugs, muscle relaxants, propranolol, ami-
triptyline, and SSRIs), the duration of prophylactic
treatment ranged from 5 to 30 months with a mean of
(16.14 ± 7.49) months. Baseline clinical profile regarding
headache duration, the duration of preventive therapy
number of headache days per month (frequency), duration
of headache per day (hours), number of days with acute
headache medications were taken, headache severity
measured by VAS and quality of life measured by HDI,
and showed no differences between both groups (Table 3).
Table 1 Doses and injection sites of Botulinum toxin
Dose (U) Muscle name




10 M. splenius capitis
10 M. semispinalis
a Two injections sites per side
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Injection techniques
Both fixed-site and follow-the-pain approaches were
adopted in the present study. Doses of BTX-A ranged from
30 to 80 IU with a mean of (50.14 ± 13.51). In all patients,
frontalis and temporalis muscles were either unilaterally or




There was a significant reduction in both number of
headache days per month (frequency), and headache
severity measured by VAS, and significant improvement of
QoL assessed by HDI in BTX-A group at 30 and 90 days
assessment when compared to the placebo group.
(Table 4). Upon assessment of changes from baseline at
90 days, there was 37.75% reduction of headache days (in
BTX-A) group versus 17.13% (in placebo) (Fig. 1),
43.68% decrease in headache severity as assessed by VAS
(in BTX-A group) versus 17.98% (in placebo), and 40.57%
decrease in HDI (in BTX-A group) versus 6.60% (in
placebo group).
Secondary efficacy variables
There was a significant decrease in the duration of head-
ache per day (hours), and number of days with acute
headache medications per month in BTX-A group at 30-
and 90-day assessment when compared to the placebo
group. (Table 5). Upon assessment of changes from base-
line at 90 days, there was 26% decrease of duration of
headache per day (hours) (in BTX-A) group versus 14.56%
(in placebo) (Fig. 2), and 42.28% decrease in number of
days with acute headache medications per month (in BTX-
A group) versus 21.94% (in placebo).
Adverse events
Treatments were generally tolerated, no systemic reactions
were noted and there were no serious injections-related
adverse events. The reported side effects were hematoma at
the site of injection, blepharoptosis, itching and pain at the
Table 2 Baseline demographic characteristics of the study
population
Variables BTX-A Placebo P value
Age (years)a 36.29 ± 7.75 36.86 ± 7.75 0.847
Sex
M 4 (28.6%) 5 (35.7%) 1.0
F 10 (71.4%) 9 (64.3%)
Smoking
Yes 5 (35.7%) 5 (35.7%) 1.0
No 9 (64.3%) 9 (64.3%)
Contraceptive pills 1/10 2/9 1.0
Educational level
Secondary 4 (28.6%) 4 (28.6%) 0.875
University 8 (57.1%) 7 (50%)
Higher level 2 (14.3%) 3 (21.4%)
a Values are mean ± SD
Table 3 Baseline clinical
profile of the study population
BTX-A Placebo P value
Headache duration (years) 4.86 ± 2.93 4.71 ± 2.27 0.886
Duration of prophylactic treatment (months) 15.93 ± 7.78 16.36 ± 7.48 0.883
Headache days/months 19.92 ± 3.75 19.21 ± 3.17 0.591
Duration of headache per day (h) 8.50 ± 1.09 8.86 ± 1.03 0.381
Number of days with acute headache medications/months 11.14 ± 2.59 10.71 ± 2.33 0.650
Headache severity (VAS) 6.21 ± 1.05 6.36 ± 1.08 0.726
HDI (baseline) 64.43 ± 8.74 60.57 ± 10.27 0.294
Table 4 Primary efficacy variables at baseline, 30 and 90 days of
study population
BTX Placebo P value
Mean SD Mean SD
Headache (days/months)
Baseline 19.93 3.75 19.21 3.17 0.591
30 days 15.00 2.25 17.50 2.03 0.005
90 days 12.07 1.94 15.92 2.16 0.000
Headache severity (VAS)
Baseline 6.21 1.05 6.36 1.08 0.726
30 days 4.79 1.05 5.86 0.86 0.007
90 days 3.50 1.22 5.21 1.19 0.001
HDI
Baseline 64.43 8.74 60.57 10.27 0.294
30 days 44.29 14.84 56.14 11.70 0.027
90 days 38.29 19.84 56.57 12.31 0.007
30 J Headache Pain (2009) 10:27–34
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site of injection (Table 6). All these side effects were
transitory and did not interfere with the patient activity, and
did not need further management.
Discussion
Based on the results of this clinical trial in 28 Egyptian
patients with CTTH, we can conclude that botulinum toxin
injection in a combination of both fixed-site and follow-
the-pain approaches is an effective and relatively safe
treatment option in patients for whom standard prophy-
lactic therapy has failed.
Several recent studies [9, 12, 24–26] have demonstrated
the effectiveness of botulinum toxin in treating several
disorders related to muscle spasticity and pain, and have
emphasized the potential role for this agent in management
of different types of chronic primary headaches including
migraine and CTTH.
Though there are large numbers of clinical studies for
the evaluation of botulinum toxin in the treatment of TTH,
yet, the results are contradictory. Many case reports and
open-label studies have shown positive results, with sig-
nificant improvement in different efficacy end points such
as such as number of headache-free days, headache
severity and duration, quality of life and tenderness to
palpation [12, 27–29]. However, in different randomized,
double-blind, placebo-controlled studies that were con-
ducted in patients with TTH, there were conflicting and
oftentimes equivocal results for the effectiveness of botu-
linum toxin [30]. While a significant improvement of
headache was detected by Relja and Telarovic [31], Porta
[6], and Smuts et al. [32], who concluded that BTX-A is an
effective prophylactic treatment for TTH in patients for
whom standard therapy has failed. Padberg et al. [33]
found no significant differences between placebo and up to
100-IU botulinum toxin that were injected in muscles with
increased tenderness in patients with CTTH in week 4, 8
and 12 post-injection. Same unsatisfactory responses were
found by Rollnik et al. [15] and Schmitt et al. [34] who
concluded that increased muscle tenderness might not be
an important pathophysiology of CTTH. This disparity in
the results of randomized trials could be attributed to
several methodological factors that include variable injec-
ted doses of BTX-A in different studies, injection sites,
which were not always standardized, and the used injection
techniques that vary across studies and have not been



























Fig. 1 Changes of headache days/months from baseline at 30 and
90 days
Table 5 Secondary efficacy variables at baseline, 30 and 90 days of
study population
BTX Placebo P value
Mean SD Mean SD
Duration of headache per day (h)
Baseline 8.50 1.09 8.86 1.03 0.381
30 days 6.93 0.83 8.07 0.92 0.002
90 days 6.29 0.91 7.57 1.34 0.006
Number of days with acute headache medications/months
Baseline 11.14 2.59 10.71 2.33 0.650
30 days 7.43 1.09 9.64 2.02 0.001







































Fig. 2 Changes of headache duration/day from baseline at 30 and
90 days
Table 6 Treatment-related adverse events
BTX-A Placebo
Hematoma at site of injection 1 1
Blepharoptosis 1 0
Itching at site of injection 0 1
Pain at site of injection 1 1
J Headache Pain (2009) 10:27–34 31
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As regards injection techniques, some researchers used
individual injection sites in the most tender muscles or
trigger points (follow-the-pain approach), while in other
studies there was a standardized injection design (fixed-site
approach) [7]. However, Ewans and Blumenfeld [35]
reported that follow-the-pain approach is more commonly
used in chronic tension-type or chronic daily headache
patients, while they recommended fixed-site approach for
patients with migraine, because follow-the-pain technique
may produce a suboptimal cosmetic outcome, and the
headaches may shift to the previously unaffected side. In
our study, we used a modified treatment paradigm using a
combination of both methods, which was previously
reported by Mathew [21]; the injected points were identi-
fied from the potential tender points in the frontal and
temporal regions, and the majority of patients were injected
in two nuchal points, close to the occipital origin of the
trapezius muscle. The injected muscles included frontalis,
temporalis, sternocleidomastoideus, trapezius, splenius
capitis, and semispinalis [22]. The adopted modified tech-
nique in our study allowed us to select the most tender
points from the commonly affected ones in those with
CTTH without apparent detection of suboptimal cosmetic
outcome.
It seems clear that there is no standardized points for
injections in headache patients, and the selected protocol
for injections and injection application techniques some-
times are regarded as important causes of lack of efficacy
of BT-A, and a larger distribution of injection points seems
compatible with better results [36].
In the current study, BTX-A is used in the range of 30–
80 IU with a mean of (50.14 ± 13.51 IU), and this goes in
accordance with Rozen and Sharma [1] who reported that
the range of doses of BTX-A used in positive studies
ranged from 15 to 100 IU (Botox) or 160 to 200 IU of
Dysport. Moreover, we injected BTX-A in small doses at
multiple sites to reduce the occurrence of side effects as
recommended by Ates [7]. To achieve this, a dilution of
4 mL of normal saline to 100 units of BTX-A was used.
The injections were administered intramuscularly to limit
discomfort and side effects that could occur by soft tissue
diffusion as intradermal injections tend to be more
uncomfortable [35]. In the placebo group we used the vial
(2 mL 0.9 NaCl), and patients received equal volumes of
saline that patients received.
Other factor to consider is the diagnostic criteria of the
included patients, some studies of the prophylactic effect of
BTX-A on headache had a broad headache diagnosis, and
others included heterogeneous group of headache disorders
[27]. Klapper et al. [37] in their double-blind, placebo-
controlled trial that enrolled 56 patients, and Robbins [38]
in an open-label study that included 79 patients used
‘‘chronic daily headache’’ as a diagnosis of included
patients. In our study, we included patients with CTTH,
and the diagnosis was established strictly following the
criteria of the HIS, and patients were eligible in this study
when they had history of failed treatment in the last
3 months with at least one prophylactic drug, and to have
the ability to distinguish between the different headache
types.
In the current study, we specified the outcome measures
as either primary or secondary efficacy variables; all effi-
cacy measures showed significant improvement in the
BTX-A group when assessed at 30 and 90 days following
injection day. The primary outcome measures were head-
ache frequency per month assessed by headache diary of
the patient, and headache severity assessed by the standard
visual analogue scale, which is a subjective measure of
headache that represents the patient’s perception of head-
ache status. We also included quality of life as a primary
efficacy point that was assessed by the 25-item beta version
HDI (b-HDI), a test with strong internal consistency/reli-
ability that used to quantify the impact of headache and its
treatment, on daily living, the items in the b-HDI were
subgrouped into either functional or emotional subscales
[20]. Our secondary efficacy points were the duration of
headache per day (hours), and number of days of symp-
tomatic therapy per month. In our study, we precisely
defined both primary and secondary efficacy points to
eliminate a major part of methodological inconsistency that
could lead to inconclusive results, and this was also rec-
ommended by Rozen and Sharma [1] who proposed that
reduction of headache frequency should be adopted as a
primary endpoint.
Various retrospective or well-designed controlled stud-
ies considered number of headache-free days (headache
frequency) as a primary outcome measure [22, 26, 39–41],
and some studies added the headache intensity (severity)
[22]. The secondary efficacy measures in different trials
were global impressions, the use of abortive headache
medications and the proportion of patients with a decrease
from baseline of 50% or more [26, 39, 41]. The determi-
nation of precise primary and secondary efficacy end points
is one of major prerequisites to avoid contradiction in
studies results. However, a point of consideration was the
higher placebo response than what was expected; this
effect was previously reported by Silberstein et al. [40].
The precise mechanism by which headache intensity and
severity are reduced is not known, based on available data,
BTX-A treatment might reduce the local release of noci-
ceptive neuropeptides [16, 42] and have either direct or
indirect effects on central sensitization [43]. In all patients
treated in this study, the injection sites included facial and
scalp regions in the distribution of the first branch of tri-
geminal nerve or cervical dermatome distribution which is
believed to be important in the proposed action of BTX-A
32 J Headache Pain (2009) 10:27–34
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which is related to the neuromodulatory effect of afferent
inputs to the trigeminal nucleus from the scalp, skin and
muscle within these regions [42]. It is hypothesized that
BTX-A has its effect not by direct muscle relaxation, but
by effects on afferent inputs into the trigeminal nucleus
[16, 42].
The follow-up period in the current study was 90 days
during which patients showed a gradual and constant trend of
improvement in their headache frequency and intensity;
however, the duration of the effect of BTX-A for CTTH was
not studied in the current trial beyond this period, because
our study focused on one-session injection with 90 days
follow-up period. A single injection might be enough to
break the cycle of chronic headaches, and there would be no
need for repeated injections [42, 44]. The potential risk of
antibody development with repeated injections and the cost
of BTX-A were another major issue, because patients had to
pay for it themselves. However, the cumulative effect of
subsequent injections of botulinum toxin in tension headache
was discussed by Ondo et al. [39] and Relja [45] who found a
lasting positive effects in long-term botulinum toxin injec-
tions, as repeated injections had a step-like therapeutic effect
and the consecutive therapeutic effect of each injection built
on the effect previously achieved.
Results of our study have also shown that BTX-A could
be safe and well-tolerated alternative therapy for CTTH. In
the current patient series, there were no serious adverse
events in the BTX-A group, and all detectable side effects
were transitory, mild to moderate in severity. These
included hematoma at the site of injection, blepharoptosis
and local pain at the site of injection. These results were
previously recognized in various reports that confirmed the
safety and tolerability of BTX-A in headache patients
[22, 26–28, 36, 39–42, 46].
In conclusion, BTX-A may be an effective and prom-
ising prophylactic treatment for CTTH in Egyptian
patients, making it an alternative to patients in whom the
standard therapeutic options have failed or can not be
tolerated. However, several questions such as injection
techniques, and doses and injection sites remain unsolved.
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